STERIS (STE) Pullback Deepens, Is It 21% Below Fair Value?
STERIS (STE) has drawn fresh attention after its recent share performance, with the price at $208.79 as of the latest close. The move comes against mixed shorter term returns and a modestly positive past 3 months.
Recent trading tells a mixed story. STERIS has slipped around 12% on a 30 day share price return and is down about 16% year to date, while the 1 year total shareholder return has declined roughly 15%. This signals fading momentum after a flatter multi year performance.
Scan beyond STERIS and review hand picked healthcare peers with resilient balance sheets and cash flows using our curated list of solid balance sheet and fundamentals (23 results) to see how this pullback compares.
STERIS now trades well below recent highs yet still carries solid revenue and net income figures. Has most of the easy gain already played out, or does this pullback leave meaningful upside that the valuation does not fully reflect?
Most Popular Narrative: 20.6% Undervalued
Sitting at $208.79 against a widely followed fair value estimate of $263.13, STERIS is framed as materially discounted, with the story focusing on how recurring chemistries, services, and capacity projects translate into earnings power over time.
Continued mix shift toward recurring chemistries and services, which now account for roughly 80% of STERIS revenue versus about 20% a decade ago, can add stability to organic revenue and support operating leverage into earnings.
See why 7 investors see STERIS as 21% undervalued.
Result: Fair Value of $263.13 (UNDERVALUED)
Still, STERIS carries real execution and cost risk, from tariff expense running in the tens of millions to large North Carolina restructuring charges that could pressure margins.
Find out about the key risks to this STERIS narrative.
Next Steps
Sentiment around STERIS in this piece may feel cautiously optimistic, so act while the details are fresh and pressure test the thesis yourself with 4 key rewards.
Looking for more ideas beyond STERIS?
Do not stop at STERIS when there are plenty of other stocks that could suit your goals, especially if you want stronger income, value, or resilience.
- Prioritise steady cash returns and scan income focused opportunities through the 7 dividend fortresses.
- Hunt for potential mispricing by checking companies that appear attractively valued using the 29 high quality undervalued stocks.
- Aim for capital protection first and review sturdier candidates via the 30 resilient stocks with low risk scores.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com